Randomized Investigation of the MitraClip Device in Heart Failure: 2nd Trial in Patients with Clinically Significant Functional Mitral Regurgitation: RESHAPE-HF2 Trial
The RESHAPE-HF2 trial demonstrated that in symptomatic heart failure patients with moderate to severe functional mitral regurgitation (MR), percutaneous mitral valve repair with MitraClip led to lower rates of first and recurrent hospitalizations for heart failure or cardiovascular death, as well as lower rates of first and recurrent hospitalizations for heart failure at 24 months, and better health status at 12 months compared to medical therapy alone, according to a study presented by Dr. Stefan Anker from Charité University Hospital, Germany, in the Hot Line session at ESC Congress 2024.
- Free Registration
-
Already have an account?Log In
A portal site of complex catheter intervention techniques
TCROSS NEWS Global is an online medical journal that provides
valuable information on Cardiovascular medicine to medical professionals
worldwide.
We bring you the latest findings and trends in all areas of
cardiovascular medicine. Please register and subscribe for unlimited access to
quality Cardiovascular News!
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.
Recommendations
